For decades, the name PCOS encouraged a narrow focus on ovarian “cysts” and fertility. That was never the full story.

On May 12, 2026, polycystic ovary syndrome (PCOS) was renamed polyendocrine metabolic ovarian syndrome (PMOS). The new name better reflects a complex, multisystem endocrine condition that can affect menstrual cycles, androgen-related symptoms, metabolic health, fertility, skin, hair, mental well-being, and long-term health.^{1, 5}

The condition itself has not suddenly changed. The name is changing so that the language more accurately reflects what the condition involves.

Why was PCOS renamed PMOS?

The former name, polycystic ovary syndrome, placed most of the attention on the ovaries and on “cysts.” That wording was incomplete and often misleading.

The updated name reflects the broader systems involved:

• Polyendocrine recognizes that multiple hormone pathways and endocrine features may be involved.
• Metabolic recognizes the condition’s relationship with glucose regulation, insulin resistance, lipid health, and cardiometabolic risk.
• Ovarian acknowledges that ovulation, menstrual cycles, and ovarian function can still be central features.

PMOS is therefore better understood as a multisystem endocrine condition with metabolic and ovarian features—not simply a disorder of ovarian cysts.^{1, 5}

The important cyst clarification

The word “cyst” is where much of the confusion begins. In PMOS, the classic ultrasound finding is usually polycystic ovarian morphology (PCOM). This refers to an increased number of small antral follicles and/or increased ovarian volume. Antral follicles are normal fluid-filled structures that contain developing eggs; they are not the same as larger benign or pathological ovarian cysts.^{2, 3}

A 2026 population-based study of 1,235 women found that those with PCOS were much more likely to have at least 20 small follicles or increased ovarian volume. However, the study found no statistically significant increase in simple cysts, paraovarian cysts, hemorrhagic cysts, endometriomas, or dermoid cysts.²

The most accurate summary is: people with PMOS often have more small ovarian follicles or increased ovarian volume, but PMOS is not defined by a higher prevalence of clinically recognized ovarian cysts.

What the name change actually means

How common is PMOS?

The World Health Organization estimates that PCOS affects approximately 10–13% of reproductive-aged women, and that up to 70% of affected women worldwide may be undiagnosed.⁴

PMOS can occur across body sizes and can persist beyond the reproductive years. Its presentation varies considerably from person to person.^{3, 4}

What are common PMOS symptoms?

Some people first notice irregular cycles. Others first notice acne, excess facial or body hair, scalp hair thinning, or difficulty conceiving.

Common clinical features may include:

• Irregular, unpredictable, or absent menstrual periods
• Signs of excess androgens, such as unwanted facial or body hair
• Acne or oily skin
• Female-pattern scalp hair thinning
• Irregular ovulation or difficulty conceiving

PMOS is also associated with broader health considerations, including increased risk of impaired glucose tolerance and type 2 diabetes, obstructive sleep apnea, cardiovascular risk factors, and endometrial hyperplasia or endometrial cancer. The overall chance of endometrial cancer remains low, but prolonged untreated amenorrhea is an important reason to seek medical care.^{3, 4}

Depression, anxiety, disordered eating, body-image distress, and reduced quality of life are also more common and deserve the same clinical attention as physical symptoms.^{3, 5}

Does the diagnosis change?

Not simply because the name changed.

In adults, the established diagnostic framework generally requires at least two of the following three features, after other possible causes have been excluded:

• Clinical or biochemical signs of androgen excess
• Ovulatory dysfunction, often reflected by irregular or absent cycles
• Polycystic ovarian morphology, assessed by ultrasound or, in adults, by anti-Müllerian hormone within the diagnostic algorithm

If irregular cycles and hyperandrogenism are both present, the 2023 International Evidence-Based Guideline states that ovarian ultrasound is not necessary for diagnosis. Anti-Müllerian hormone should not be used as a standalone diagnostic test.³

Adolescent diagnosis requires additional caution, and ovarian ultrasound is not recommended for diagnosing PMOS in adolescents because normal pubertal development can resemble some adult features.³

What does evidence-based PMOS care include?

Care should be individualized according to symptoms, age, metabolic health, fertility goals, medication tolerance, and personal preferences.

The 2023 International Evidence-Based Guideline recommends healthy lifestyle support for all women with PCOS/PMOS. Benefits can occur even without weight loss, and care should avoid weight stigma.³

There is no single “PMOS diet” proven to be best for everyone. The guideline found no evidence that one dietary composition is superior for anthropometric, metabolic, hormonal, reproductive, or psychological outcomes. Sustainable healthy eating tailored to individual preferences and goals is the more evidence-based approach.³

General physical-activity guidance includes 150–300 minutes of moderate-intensity activity per week, or 75–150 minutes of vigorous activity, together with muscle-strengthening activity on two nonconsecutive days per week. Any increase in movement can be beneficial, and the plan should be realistic and individualized.³

Medical options may include combined oral contraceptive pills for irregular cycles or hirsutism, metformin for selected metabolic indications, and letrozole for ovulation induction in appropriate cases of anovulatory infertility. These are clinician-guided decisions rather than universal protocols.³

Where does nutrition support fit?

Nutrition support can be part of a broader wellness routine, but it does not replace diagnosis, metabolic screening, or individualized medical care.

Inositol has been studied in women with PCOS/PMOS. The 2023 International Evidence-Based Guideline states that it may be considered according to individual preferences and values, noting limited harm and possible improvement in some metabolic measures. At the same time, the guideline reports limited clinical benefits for outcomes such as ovulation, hirsutism, and weight, and it does not recommend a specific type, dose, combination, or ratio because the quality of evidence remains insufficient.³

This is the appropriate evidence-based balance: inositol may be a supportive option for some people, but it should not be presented as a treatment or cure for PMOS.

Where WrenLife Hormone Health fits

PMOS care should be comprehensive and may include balanced nutrition, movement, sleep, mental-health support, appropriate laboratory assessment, and clinician-guided treatment when needed.

WrenLife Hormone Health includes myo-inositol and D-chiro-inositol in a 40:1 ratio, plus vitamin D3, magnesium, chromium, and zinc. It is formulated to support women’s cycle health, healthy hormone signaling, and daily metabolic wellness as part of a consistent routine.*

The 40:1 ratio is part of the WrenLife formulation; current international guidance does not endorse any specific inositol type, dose, combination, or ratio for PMOS.³

WrenLife Hormone Health is not a treatment for PMOS. Supplements should be discussed with a healthcare professional, particularly during pregnancy or breastfeeding or when using prescription medications.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

What to ask your healthcare professional

If you think you may have PMOS, consider asking about a complete evaluation rather than focusing only on ovarian ultrasound:

• Do my cycle pattern and androgen-related symptoms fit the diagnostic framework?
• Which laboratory tests are appropriate, and which alternative causes should be excluded?
• Which test should be used to assess my glucose status, and should my lipids and blood pressure be checked?
• Should I be assessed for sleep-apnea symptoms, depression, anxiety, or disordered eating?
• Which lifestyle, medication, fertility, and nutrition-support options fit my goals?

FAQ

Did PCOS officially change to PMOS?

Yes. On May 12, 2026, the condition previously known as polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome, or PMOS. A transition period is planned, so both terms will remain in use for several years.¹

What does PMOS stand for?

PMOS stands for polyendocrine metabolic ovarian syndrome. The name reflects the condition’s endocrine, metabolic, and ovarian features.¹

Does PMOS mean I have ovarian cysts?

Not necessarily. PMOS is not defined by clinically recognized ovarian cysts. Some people have more small ovarian follicles or increased ovarian volume, while others can be diagnosed without polycystic ovarian morphology.^{2, 3}

Why was it called “polycystic”?

The former name arose from the ultrasound appearance of ovaries containing many small follicles. Those follicles are not the same as larger benign or pathological ovarian cysts.^{2, 3}

Is PMOS only about fertility?

No. PMOS can affect ovulation and fertility, but it is also associated with androgen-related symptoms, metabolic health, sleep, skin, hair, mental health, and longer-term health risks.^{3, 5}

Can supplements treat PMOS?

No dietary supplement should be presented as treating, curing, or preventing PMOS. Supplements may support normal body functions and a healthy routine, but they do not replace medical assessment or clinician-guided care.

Is inositol useful for PMOS?

Inositol may be considered based on individual preferences and values. The international guideline notes possible improvement in some metabolic measures but limited clinical benefits, and it does not recommend a specific type, dose, combination, or ratio because the evidence is not strong enough.³

Scientific references

1. Endocrine Society. Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide. Published May 12, 2026.
2. Piltonen TT, Kuusiniemi E, Teede HJ, et al.; WENDY Research Group. Ovarian Cysts in Polycystic Ovary Syndrome. JAMA Internal Medicine. Published online May 11, 2026. Corrected online June 15, 2026. doi:10.1001/jamainternmed.2026.1370.
3. Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology & Metabolism. 2023;108(10):2447–2469. doi:10.1210/clinem/dgad463.
4. World Health Organization. Polycystic ovary syndrome. Fact sheet. Updated January 22, 2026.
5. Stener-Victorin E, Teede H, Norman RJ, et al. Polycystic ovary syndrome. Nature Reviews Disease Primers. 2024;10:27. doi:10.1038/s41572-024-00511-3.